非小细胞肺癌 (NSCLC) 占所有肺癌的 85%，其预后较差，5 年生存率为 19%，主要是因为 NSCLC 诊断时已是晚期且已转移。阶段。尽管最近的治疗取得了进展，但约 50% 的 NSCLC 患者会出现脑转移 (BM)。对于有症状的患者和单发脑转移瘤的患者，可以单独进行手术BM治疗；对于不适合手术或脑病灶直径在5-30 mm范围内的脑病灶少于4个的患者，可以联合立体定向放射治疗（RT），或可以对大量或大型脑转移进行全脑放疗。然而，放射抗性 (RR) 总是会阻止 RT 的作用。 RR 的几种机制已被描述，包括缺氧、细胞应激、癌症干细胞的存在、细胞凋亡和/或自噬失调、细胞周期失调、细胞代谢变化、上皮间质转化、程序性细胞死亡过度表达‑配体 1 和激活多个信号通路；然而，Hippo 信号通路在 RR 中的作用尚不清楚。 NSCLC 中 Hippo 通路的失调会导致转移特性，目前正在开发针对该通路的抑制剂。因此，有必要评估抑制 Hippo 通路，特别是效应子 yes 相关蛋白 1 对肺癌脑转移的影响。

The prognosis for patients with non‑small cell lung cancer (NSCLC), a cancer type which represents 85% of all lung cancers, is poor with a 5‑year survival rate of 19%, mainly because NSCLC is diagnosed at an advanced and metastatic stage. Despite recent therapeutic advancements, ~50% of patients with NSCLC will develop brain metastases (BMs). Either surgical BM treatment alone for symptomatic patients and patients with single cerebral metastases, or in combination with stereotactic radiotherapy (RT) for patients who are not suitable for surgery or presenting with fewer than four cerebral lesions with a diameter range of 5‑30 mm, or whole‑brain RT for numerous or large BMs can be administered. However, radioresistance (RR) invariably prevents the action of RT. Several mechanisms of RR have been described including hypoxia, cellular stress, presence of cancer stem cells, dysregulation of apoptosis and/or autophagy, dysregulation of the cell cycle, changes in cellular metabolism, epithelial‑to‑mesenchymal transition, overexpression of programmed cell death‑ligand 1 and activation several signaling pathways; however, the role of the Hippo signaling pathway in RR is unclear. Dysregulation of the Hippo pathway in NSCLC confers metastatic properties, and inhibitors targeting this pathway are currently in development. It is therefore essential to evaluate the effect of inhibiting the Hippo pathway, particularly the effector yes‑associated protein‑1, on cerebral metastases originating from lung cancer.